senator: sir, i have the numbers in front of me. how can you keep this secret from the public?. december 2013  (11).

former novartis exec to lead cambridge diabetes startup semma., and bones, and it�s not clear how the drugs will affect them after long-term use...

�the kind of review being proposed does not, at least initially, appear to bring anything new or needed to is already a robust system of oversight,� mogulof said in the statement..